Cargando…
Lipoprotein(a) in Cardiovascular Diseases
Lipoprotein(a) (Lp(a)) is an LDL-like molecule consisting of an apolipoprotein B-100 (apo(B-100)) particle attached by a disulphide bridge to apo(a). Many observations have pointed out that Lp(a) levels may be a risk factor for cardiovascular diseases. Lp(a) inhibits the activation of transforming g...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591100/ https://www.ncbi.nlm.nih.gov/pubmed/23484137 http://dx.doi.org/10.1155/2013/650989 |
_version_ | 1782261980986343424 |
---|---|
author | Malaguarnera, Michele Vacante, Marco Russo, Cristina Malaguarnera, Giulia Antic, Tijana Malaguarnera, Lucia Bella, Rita Pennisi, Giovanni Galvano, Fabio Frigiola, Alessandro |
author_facet | Malaguarnera, Michele Vacante, Marco Russo, Cristina Malaguarnera, Giulia Antic, Tijana Malaguarnera, Lucia Bella, Rita Pennisi, Giovanni Galvano, Fabio Frigiola, Alessandro |
author_sort | Malaguarnera, Michele |
collection | PubMed |
description | Lipoprotein(a) (Lp(a)) is an LDL-like molecule consisting of an apolipoprotein B-100 (apo(B-100)) particle attached by a disulphide bridge to apo(a). Many observations have pointed out that Lp(a) levels may be a risk factor for cardiovascular diseases. Lp(a) inhibits the activation of transforming growth factor (TGF) and contributes to the growth of arterial atherosclerotic lesions by promoting the proliferation of vascular smooth muscle cells and the migration of smooth muscle cells to endothelial cells. Moreover Lp(a) inhibits plasminogen binding to the surfaces of endothelial cells and decreases the activity of fibrin-dependent tissue-type plasminogen activator. Lp(a) may act as a proinflammatory mediator that augments the lesion formation in atherosclerotic plaques. Elevated serum Lp(a) is an independent predictor of coronary artery disease and myocardial infarction. Furthermore, Lp(a) levels should be a marker of restenosis after percutaneous transluminal coronary angioplasty, saphenous vein bypass graft atherosclerosis, and accelerated coronary atherosclerosis of cardiac transplantation. Finally, the possibility that Lp(a) may be a risk factor for ischemic stroke has been assessed in several studies. Recent findings suggest that Lp(a)-lowering therapy might be beneficial in patients with high Lp(a) levels. A future therapeutic approach could include apheresis in high-risk patients in order to reduce major coronary events. |
format | Online Article Text |
id | pubmed-3591100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35911002013-03-12 Lipoprotein(a) in Cardiovascular Diseases Malaguarnera, Michele Vacante, Marco Russo, Cristina Malaguarnera, Giulia Antic, Tijana Malaguarnera, Lucia Bella, Rita Pennisi, Giovanni Galvano, Fabio Frigiola, Alessandro Biomed Res Int Review Article Lipoprotein(a) (Lp(a)) is an LDL-like molecule consisting of an apolipoprotein B-100 (apo(B-100)) particle attached by a disulphide bridge to apo(a). Many observations have pointed out that Lp(a) levels may be a risk factor for cardiovascular diseases. Lp(a) inhibits the activation of transforming growth factor (TGF) and contributes to the growth of arterial atherosclerotic lesions by promoting the proliferation of vascular smooth muscle cells and the migration of smooth muscle cells to endothelial cells. Moreover Lp(a) inhibits plasminogen binding to the surfaces of endothelial cells and decreases the activity of fibrin-dependent tissue-type plasminogen activator. Lp(a) may act as a proinflammatory mediator that augments the lesion formation in atherosclerotic plaques. Elevated serum Lp(a) is an independent predictor of coronary artery disease and myocardial infarction. Furthermore, Lp(a) levels should be a marker of restenosis after percutaneous transluminal coronary angioplasty, saphenous vein bypass graft atherosclerosis, and accelerated coronary atherosclerosis of cardiac transplantation. Finally, the possibility that Lp(a) may be a risk factor for ischemic stroke has been assessed in several studies. Recent findings suggest that Lp(a)-lowering therapy might be beneficial in patients with high Lp(a) levels. A future therapeutic approach could include apheresis in high-risk patients in order to reduce major coronary events. Hindawi Publishing Corporation 2013 2012-12-30 /pmc/articles/PMC3591100/ /pubmed/23484137 http://dx.doi.org/10.1155/2013/650989 Text en Copyright © 2013 Michele Malaguarnera et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Malaguarnera, Michele Vacante, Marco Russo, Cristina Malaguarnera, Giulia Antic, Tijana Malaguarnera, Lucia Bella, Rita Pennisi, Giovanni Galvano, Fabio Frigiola, Alessandro Lipoprotein(a) in Cardiovascular Diseases |
title | Lipoprotein(a) in Cardiovascular Diseases |
title_full | Lipoprotein(a) in Cardiovascular Diseases |
title_fullStr | Lipoprotein(a) in Cardiovascular Diseases |
title_full_unstemmed | Lipoprotein(a) in Cardiovascular Diseases |
title_short | Lipoprotein(a) in Cardiovascular Diseases |
title_sort | lipoprotein(a) in cardiovascular diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591100/ https://www.ncbi.nlm.nih.gov/pubmed/23484137 http://dx.doi.org/10.1155/2013/650989 |
work_keys_str_mv | AT malaguarneramichele lipoproteinaincardiovasculardiseases AT vacantemarco lipoproteinaincardiovasculardiseases AT russocristina lipoproteinaincardiovasculardiseases AT malaguarneragiulia lipoproteinaincardiovasculardiseases AT antictijana lipoproteinaincardiovasculardiseases AT malaguarneralucia lipoproteinaincardiovasculardiseases AT bellarita lipoproteinaincardiovasculardiseases AT pennisigiovanni lipoproteinaincardiovasculardiseases AT galvanofabio lipoproteinaincardiovasculardiseases AT frigiolaalessandro lipoproteinaincardiovasculardiseases |